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Two basic and clinical researches accomplished during the recent years on embryonic and adult stem cells constituted a mutation in 
regenerative therapy. These cells can be used for treating some degenerative diseases. Between them, age-related functional defects, 
hematopoietic and immune system disorders, heart failures, chronic liver injuries, diabetes, Parkinson’s and Alzheimer’s diseases, 
arthritis and muscular, skin, lung, eye, and digestive disorders, aggressive and regressive cancers can be treated by cell therapies. This 
review focused on types of stem cells used in regenerative medicine.
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1. Context
Stem cells were ﬁrst studied in 1963, when bone mar-
row cells were injected into irradiated mice and no-
ticed tumors growth in mice spleens. They concluded 
that any nodule arose from a single bone marrow cell. 
In addition, they found that these cells were capable 
of self-renewal. There are two main types of stem cells, 
embryonic and non-embryonic types. Embryonic stem 
cells are totipotent and can differentiate into all three 
embryonic germ layers and non-embryonic stem cells, 
known as adult stem cells, are multipotent and their 
ability to differentiate into different cell types assumed 
to be more limited (1).
2. Embryonic State
2.1. Embryonic Stem Cells
Human embryonic stem cells (ES cells) are undifferen-
tiated cells that have self-renewal and differentiate into 
all cell types. The derivation of ES cells from mouse was 
ﬁrst reported in 1981 and in 1998 the derivations of hu-
man ES cell lines were reported. Embryonic stem cells are 
isolated from inner cell mass (ICM) of embryo. ICM cells 
have the potential to generate any cell type, but after im-
plantation, these cells differentiate to other cell types. ES 
cells can be isolated by immunosurgery from the inner 
cell mass of embryo during the blastocyst phase and are 
usually grown on feeder layers consisting of embryonic 
ﬁbroblast cells. Recent reports showed that these cells 
can be grown without using a feeder layer. These cells 
have demonstrated longevity in culture by maintaining 
their undifferentiated state for 80 passages. Recently 
studies showed that human hESCs differentiate into ke-
ratinocytes, chondrocyte and osteocyte (2-4) (Figure 1).
Figure 1. Human Blastocyst
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2.2. Embryonic Germ Cells
In 1998 isolation, culture and characterization of germ 
cells derived from the gonadal ridge of human tissue ob-
tained were shown. Embryonic germ (EG) cells are derived 
from primordial germ line cells in primitive fetal tissue. 
The range of potential fates would be relatively limited 
compared to embryonic stem cells, because EG cells are 
much further along in evolvement (5-9 weeks). Fetal tis-
sue may provide deposited progenitors, but the possibil-
ity of large scale sourcing and construction of products 
using such cells is doubtful. Furthermore, behavior of 
these cells in vivo is not well understood; much research 
would be required to avoid unwanted outcomes, includ-
ing ectopic tissue formation, tumor induction or other 
unusual development (5, 6).
2.3. Amniotic Epithelial Cells
Amniotic epithelial cells (AECs) are derived from the 
amniotic membrane in placenta. These cells express the 
markers present in pluripotent embryonic stem cells and 
embryonic germ cells, such as Oct-4, Nanog and alkaline 
phosphatase (AP). Moreover, these cells differentiate as 
ESCs and EGCs in the cell lineages from three germ layers. 
Because of the observation that they proliferate at a high 
rate without apparent loss of pluripotency or teratogenic 
potential when transplanted in immunodeﬁcient ani-
mals, amniotic fluid stem cells were credited with being 
a safer alternative to hESCs (7, 8).
2.4. Amniotic Fluid-Derived Stem Cells
In 2007, isolation of multipotent stem cells from amni-
otic liquid was performed. These undifferentiated cells 
were found to express some embryonic stem cell markers. 
These cells show a mediocre stage between the two types 
of stem cells, ESCs and non-ESCs. Amniotic fluid-derived 
stem cells were found to expand extensively. This result 
was obtained without the need to use a feeder layer, dou-
bling and retaining long telomeres to over 250 population 
doublings. These cells did form teratomas in vivo. These 
cells have the capability to differentiate into functional 
cells corresponding to any of the three main embryonic 
germ layers. These cells were able to give rise to adipo-
genic, osteogenic, myogenic, endothelial, neuronal and 
hepatic cells. The ability to derivation genetically and phe-
notypically constant pluripotent cells from such a widely 
and easily available source would potentially have an em-
phasis on regenerative therapy in the future (9).
2.5. Umbilical Cord Blood Stem Cells
In 1980s, umbilical cord blood stem cells were recog-
nized as an important source of HSCS. Blood from the 
placenta and umbilical cord is a valuable source of he-
matopoietic stem cells. Cord blood stem cell technology 
has many advantages over embryonic and other adult 
stem cells for several reasons including; (A) cord blood 
displays a potentially unlimited source of stem cells that 
can in theory be gathered at every birth; (B) cord blood 
is relatively simple to process and store using tried and 
tested technology and is biologically stable once frozen 
in liquid nitrogen; (C) collection of cord blood is a non-
invasive method. If cord blood is not collected, it is dis-
carded as biological waste; and (D) cord blood carries low 
risk of infection (10, 11).
3. Non Embryonic State
3.1. Bone Marrow Stem Cells
3.1.1. Bone Marrow Hematopoietic Stem Cells
Hematopoietic stem cells have speciﬁc morphological 
appearances and cell-surface markers that allow them 
to be labeled and tracked in the blood flow and goal tis-
sues or to be isolated and cultured in laboratory. Hemato-
poietic stem cells represent less than 0.05% of the whole 
bone marrow, but have the potential to reconstitute all 
blood forming lineages (8).
3.1.2. Bone Marrow Stromal Stem Cells
Scientists described the marrow stroma as a heteroge-
neous population of connective tissue cells. These cells 
support structurally marrow hematopoiesis. This struc-
ture of heterogeneous cells constitutes the niche of hae-
matopoietic stem cells, supporting bone marrow cells. 
The term bone marrow stromal cell (BMSCs) was applied 
to isolated bone marrow cells with potential to form con-
nective tissues. Among these BMSCs, there is a subpopula-
tion of undifferentiated multipotent cells able to gener-
ate the mesenchyme. These cells present in all postnatal 
tissues and is deﬁned as mesenchymal stem cells. These 
cells differentiated into multiple mesenchymal cell lin-
eages in laboratory, including bone, ligament, adipose, 
cartilage and muscle. BMSCs or MSCs are usually isolated 
from the mononuclear layer of bone marrow after sepa-
ration by density gradient centrifugation. These mono-
nuclear cells are cultured in culture media containing 10-
15% fetal calf or autologous serum. BMSCs adhere to the 
tissue culture plastic, leaving small adherent ﬁbroblast-
like cells. These cells divide and proliferate rapidly (12, 13).
3.2. Multipotent Adult Progenitor Cells
The adult bone marrow has a heterologous population 
of stem cells, named multipotent adult progenitor cells 
and organize a population of stem cells isolated from or 
closely related to embryonic stem cells (14).
3.3. Mesenchymal Stem Cells
Mesenchymal stem cells (MSCs) are capable of self-
renewal and differentiation into multiple cells. MSCs 
are multipotent and easily derived from a variety of tis-
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sues, containing fat, skin and bone marrow. Now, bone 
marrow and gingiva are considered as prime sources of 
MSCs. These cells are ﬁbroblastic in appearance and can 
be populated for many passages. Populations of mesen-
chymal stem cells are strongly adherent. Mesenchymal 
stem cells can give rise to many kinds of connective tis-
sue cells containing those responsible for remodeling 
of cartilage, bone, fat and vascular tissue. MSCs can be 
derived from circulating blood, as well as diverse non-
hematopoietic tissues such as synovium, adipose tissue, 
trabecular bone, dermis, dental pulp and lung. Human 
adult mesenchymal stem cells are non-hematopoietic, 
adherent ﬁbroblast-like cells with capacity of self-renew-
al and potential for multilineage differentiation. Isolated 
MSCs present surface markers such as Thy-1 (CD90), SH-2/
endoglin (CD105), SH-3/4 (CD73), b-1-integrin (CD29) and 
CD44 and are negative for hematopoietic markers such 
as CD34, CD14 and CD45 (15, 16).
3.4. Neural Stem Cells
Neural stem cells can self-renew and have the capacity 
to generate glial and neuronal lineages. Neuronal stem 
cells have been isolated from the brains of embryos and 
adults. Adult neural stem cells have the potential to dif-
ferentiate into cell types of the brain, mainly oligoden-
drocytes, astrocytes and neurons and used in transplants 
for Parkinson’s disease. These cells may be multipotent. 
In brain-injury models, neural stem cells (NSCs) prolifer-
ate in those neurogenic regions and migrate toward the 
site of damage (17).
3.5. Pancreatic Stem Cells
The mammalian adult pancreas has three tissue types; 
the ductal tree, the exocrine acini and the endocrine is-
lets of Langerhans. Multipotent cell progenitors have 
been recognized within the ducts and islets in adult ro-
dent and human pancreas. Pancreatic stem cells (PSCs) 
were derived from human fetal pancreas, which present 
stem cell markers nestin, ATP binding cassette transport-
er (ABCG2) and KIT (18).
3.6. Skin Stem Cells
Skin is the largest organ in the body. Skin is derived 
from the embryonic ectoderm germ layer. In 2001, isola-
tion of multipotent cells from the dermis was reported. 
These cells proliferated and differentiated in culture to 
produce both neural and mesodermal cells, including 
neurones, glia, smooth muscle and adipocytes. Nestin-
positive, skin-derived precursors (SKPs) are a different 
type of stem cells. Most neural cells generated by SKPs are 
similar to peripheral neurones and Schwann cells. Thus, 
SKPs represent an embryonic neural crest-related precur-
sor. SKPs can be derived from human tissue, including as 
little as 1-2 cm of foreskin sample and small punch biop-
sies from the scalp. SKPs are an available source of neural 
precursors, which can be used for regenerative medicine 
of the nervous system. Some studies have shown that the 
upper region of hair follicles, the bulge area, constitutes 
the niche of multipotent stem cells, which are responsi-
ble for long-term growth of hair follicles and epidermis 
regeneration after tissue injury. More speciﬁcally, mul-
tipotent epithelial stem cells (bESCs) within the bulge 
area, which express CD34, K5 and a 6 integrin, are able to 
proliferate and give rise to the follicular epithelium, as 
well as new cells constituting IFE and sebaceous glands 
after severe injury. The bulge area in adult mammalian 
hair follicle also contains a pluripotent epidermal neu-
ral crest stem cell (eNCSC) population that shows several 
properties similar to embryonic neural crest stem cells. 
The pluripotent eNCSCs in the bulge area are also able to 
self-renewal and give rise to multiple cells in vivo, includ-
ing melanocytes, neurons, Schwann cells, smooth muscle 
cells and chondrocytes (19-21).
3.7. Cardiac Stem Cells
Cardiac stem cells are undifferentiated and present 
in the adult heart of mammals. These cells mediate en-
dogenous mechanisms for repair and substitution of 
ongoing cells within the adult heart. Cardiac progeni-
tor cells are multipotent and give rise to cardiomyo-
cytes and coronary vessels in vivo, such possessing the 
substantial properties of stem cells. Cardiac stem cells 
can be isolated from patients and cultured ex vivo to 
generate great numbers of cells. A recent report dem-
onstrated that cardiac stem cells increase in number 
after MI, but in the chronic step, the numbers fall and 
the residual cardiac stem cells have less regenerative 
capacity. There are no clinical trials of human cardiac 
stem cells (22, 23).
3.8. Fat Stem Cells
Human adipose tissue is a source of multipotent stem 
cells. Adipose derived stem cells (ADSCs) can be induced 
to differentiate in vitro into various other cell lines, in-
cluding chondrogenic, adipogenic, osteogenic, hepatic 
and neurogenic lineages. Studies showed that phenotype 
and genotype of these cells at a transcriptional level are 
fully like to those of BMSCs.
ADSCs are a good source for regenerative medicine and 
can be maintained for long periods with population dou-
blings and low senescence. Although the bone marrow is 
a good source of stem cells, its derivation is an invasive 
method and the number of derived cells can be low and 
age dependent. In addition, only 0.01-0.001% of mononu-
clear cells derived from the bone marrow lead to colony-
forming units, but adipose tissue can yield large amounts 
of stem cells and obtained in abundance (24-26).
3.9. Olfactory Adult Stem Cells
Olfactory adult stem cells have been isolated from the 
human olfactory mucosa cells, the lining of nose in-
volved in the feeling of olfaction (27, 28) (Figure 2).
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Figure 2. Locations of Non-Embryonic Stem Cells in the Body
Figure 3. IPS Colony on Feeder Layer
4. Induced Pluripotent Stem Cells
In a study skin ﬁbroblasts reprogramed to induce plu-
ripotent stem cells named iPS cells using viral vector con-
taining four transcription factors Oct-4, Sox-2, c-Myc and 
Klf4. These cells represent properties the same as ESCs. 
Skin biopsies from patients are obtained and skin ﬁbro-
blasts are then reprogrammed into iPSCs. These patient 
speciﬁc-iPSC lines can be differentiated into different 
cells. A number of diseases have been modeled such as 
amyotrophic lateral sclerosis, spinal muscular atrophy, 
Parkinson’s disease, sickle cell anemia and type I diabetes 
mellitus (29, 30) (Figure 3).
Authors’ Contributions
All authors participated equally in this study.
Funding/Support
This study was conducted by ﬁnancial support of Skin 
Zare S et al.
5J Skin Stem Cell. 2014;1(3):e28471
and Stem Cell Research Center, Tehran University of Medi-
cal Sciences, Tehran, Iran.
References
1.       Bajada S, Mazakova I, Richardson JB, Ashammakhi N. Updates on 
stem cells and their applications in regenerative medicine. J Tis-sue Eng Regen Med. 2008;2(4):169–83.
2.       Evans MJ, Kaufman MH. Establishment in culture of pluripoten-
tial cells from mouse embryos. Nature. 1981;292(5819):154–6.
3.       Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel 
JJ, Marshall VS, et al. Embryonic stem cell lines derived from hu-
man blastocysts. Science. 1998;282(5391):1145–7.
4.       Thembi Rhino M. Rhino Fertility Clinic. Johannesburg: Frog-IT; 
2014. Available from: http://www.rhinofertility.co.za.
5.       Shamblott MJ, Axelman J, Wang S, Bugg EM, Littleﬁeld JW, 
Donovan PJ, et al. Derivation of pluripotent stem cells from 
cultured human primordial germ cells. Proc Natl Acad Sci U S A. 
1998;95(23):13726–31.
6.       International Stem Cell I, Adewumi O, Aflatoonian B, Ahrlund-
Richter L, Amit M, Andrews PW, et al. Characterization of human 
embryonic stem cell lines by the International Stem Cell Initia-
tive. Nat Biotechnol. 2007;25(7):803–16.
7.       Tamagawa T, Ishiwata I, Saito S. Establishment and characteriza-
tion of a pluripotent stem cell line derived from human amni-
otic membranes and initiation of germ layers in vitro. Hum Cell. 
2004;17(3):125–30.
8.       Hmadcha A, Dominguez-Bendala J, Wakeman J, Arredouani 
M, Soria B. The immune boundaries for stem cell based thera-
pies: problems and prospective solutions. J Cell Mol Med. 
2009;13(8A):1464–75.
9.       De Coppi P, Bartsch GJ, Siddiqui MM, Xu T, Santos CC, Perin L, et al. 
Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol. 2007;25(1):100–6.
10.       Barker JN, Wagner JE. Umbilical cord blood transplantation: 
current practice and future innovations. Crit Rev Oncol Hematol. 
2003;48(1):35–43.
11.       Hollands P. Cord Blood Stem Cells-The Basic Science. In: Bhat-
tacharya N, Stubbleﬁeld P editors. Frontiers of Cord Blood Science.. 
London: Springer-Verlag; 2009. pp. 19–25.
12.       Maniatopoulos C, Sodek J, Melcher AH. Bone formation in vitro 
by stromal cells obtained from bone marrow of young adult rats. Cell Tissue Res. 1988;254(2):317–30.
13.       Caplan AI. Review:Mesenchymal Stem Cells: Cell–Based Recon-
structive Therapy in Orthopedics. Tissue Eng. 2005;11(7-8):1198–211.
14.       Jiang Y, Vaessen B, Lenvik T, Blackstad M, Reyes M, Verfaillie 
CM. Multipotent progenitor cells can be isolated from post-
natal murine bone marrow, muscle, and brain. Exp Hematol. 
2002;30(8):896–904.
15.       Tomar GB, Srivastava RK, Gupta N, Barhanpurkar AP, Pote ST, 
Jhaveri HM, et al. Human gingiva-derived mesenchymal stem 
cells are superior to bone marrow-derived mesenchymal stem 
cells for cell therapy in regenerative medicine. Biochem Biophys Res Commun. 2010;393(3):377–83.
16.       Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mes-
enchymal stem cells: their phenotype, differentiation capacity, 
immunological features, and potential for homing. Stem Cells. 
2007;25(11):2739–49.
17.       Brignier AC, Gewirtz AM. Embryonic and adult stem cell therapy. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S336–44.
18.       Suen PM, Leung PS. Pancreatic stem cells: a glimmer of hope for 
diabetes? JOP. 2005;6(5):422–4.
19.       Sieber-Blum M, Grim M. The adult hair follicle: cradle for plu-
ripotent neural crest stem cells. Birth Defects Res C Embryo Today. 
2004;72(2):162–72.
20.       Kuang S, Kuroda K, Le Grand F, Rudnicki MA. Asymmetric self-
renewal and commitment of satellite stem cells in muscle. Cell. 
2007;129(5):999–1010.
21.       Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, et al. A 
tumorigenic subpopulation with stem cell properties in mela-
nomas. Cancer Res. 2005;65(20):9328–37.
22.       Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, 
et al. Adult cardiac stem cells are multipotent and support myo-
cardial regeneration. Cell. 2003;114(6):763–76.
23.       Urbanek K, Torella D, Sheikh F, De Angelis A, Nurzynska D, Silves-
tri F, et al. Myocardial regeneration by activation of multipotent 
cardiac stem cells in ischemic heart failure. Proc Natl Acad Sci U S A. 2005;102(24):8692–7.
24.       Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, et al. 
Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 2002;13(12):4279–95.
25.       Erickson GR, Gimble JM, Franklin DM, Rice HE, Awad H, Guilak 
F. Chondrogenic potential of adipose tissue-derived stro-
mal cells in vitro and in vivo. Biochem Biophys Res Commun. 
2002;290(2):763–9.
26.       Seo MJ, Suh SY, Bae YC, Jung JS. Differentiation of human adipose 
stromal cells into hepatic lineage in vitro and in vivo. Biochem Biophys Res Commun. 2005;328(1):258–64.
27.       Murrell W, Feron F, Wetzig A, Cameron N, Splatt K, Bellette B, et 
al. Multipotent stem cells from adult olfactory mucosa. Dev Dyn. 
2005;233(2):496–515.
28.       Genetic Science Learning Center.. Genetic Science Learning Center at The University of Utah. Salt Lake City: University of Utah; 2015. 
Available from: http://learn.genetics.utah.edu/.
29.       Bilic J, Izpisua Belmonte JC. Concise review: Induced pluripotent 
stem cells versus embryonic stem cells: close enough or yet too 
far apart? Stem Cells. 2012;30(1):33–41.
30.       The University of Edinburgh.. Europe's stem cell hub. Edinburgh: 
The University of Edinburgh; 2015. Available from: http://www.
eurostemcell.org.
